Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV002249947 | SCV002519646 | uncertain significance | Congenital factor VII deficiency | 2023-08-31 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002261461 | SCV002541598 | uncertain significance | not provided | 2022-12-23 | criteria provided, single submitter | clinical testing | PM1_supporting, PS4_moderate |
Prevention |
RCV004753546 | SCV005341480 | uncertain significance | F7-related disorder | 2024-06-07 | no assertion criteria provided | clinical testing | The F7 c.599T>G variant is predicted to result in the amino acid substitution p.Ile200Ser. This variant has been reported in cohorts of individuals with Factor VII deficiency / blood disorders (Reported as 8926G>T I140S, Rodrigues et al. 2003. PubMed ID: 12695753; Reported as c.347T>G p.Ile116Ser in Table S3, Baz et al. 2021. PubMed ID: 34272389; Pankratz et al. 2022. PubMed ID: 35552711). Also, this variant was shown to be significantly associated with an increased risk of venous thromboembolism (Pankratz et al. 2022. PubMed ID: 35552711). This variant is reported in 0.71% of alleles in individuals of African descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |